Recent Company News

• 05:03 AM ET Mar 30, 2026
  

  Sino Biopharmaceutical completes acquisition of Hygieia; deal was announced on 13-Jan (HK$5.85, 0.00)

• 04:47 AM ET Mar 26, 2026
  

  StreetAccount Metrics Recap - Sino Biopharmaceutical FY Earnings (HK$5.82, 0.00)

• 04:37 AM ET Mar 26, 2026
  

  Sino Biopharmaceutical reports FY underlying profit attributable CNY4.54B vs StreetAccount CNY4.89B (HK$5.82, 0.00)

• 08:28 AM ET Mar 23, 2026
  

  StreetAccount Consensus Metrics Preview - Sino Biopharmaceutical FY Earnings

• 06:15 AM ET Mar 17, 2026
  

  Sino Biopharmaceutical receives NMPA clinical trial approval for TRD221 for treatment of osteoarthritis (HK$6.05, 0.00)

• 05:17 AM ET Mar 12, 2026
  

  Sino Biopharmaceutical reaches pre-specified primary endpoints for phase III clinical trial of TQB3454 for advanced biliary tract cancer (HK$6.03, 0.00)

• 07:04 AM ET Mar 11, 2026
  

  Sino Biopharmaceutical receives NMPA clinical trial approval for TQB3205 "pan-KRAS inhibitor" for treatment of advanced malignant tumors (HK$6.10, 0.00)

• 10:36 PM ET Mar 04, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 09:30 PM ET Mar 03, 2026
  

  StreetAccount Sector Summary - China Healthcare February Recap

• 05:18 PM ET Mar 03, 2026
  

  Chia Tai Tianqing Pharmaceutical enters into an exclusive license agreement with Sanofi subsidiary for global development, manufacturing and commercialization of rovadicitinib (HK$5.71, 0.00)